sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Lumateperone

Medicine · Atypical Antipsychotic

Lumateperone

CAPLYTA is indicated for: Treatment of schizophrenia in adults.

Medication guideLabel updated 2025-06-20

Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of CAPLYTA have not been established in pediatric patients.

Drug facts

Used for
  • Treatment of schizophrenia in adults. Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. Adjunctive therapy with antidepressants
  • for the treatment of major depressive disorder (MDD) in adults. CAPLYTA is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. Adjunctive therapy with antidepressants
  • for the treatment of major depressive disorder (MDD) in adults.
How to take it
Take CAPLYTA exactly as your healthcare provider tells you to take it.

What it is used for

CAPLYTA is indicated for: Treatment of schizophrenia in adults. Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

CAPLYTA is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

The most important thing to know

CAPLYTA may cause serious side effects, including: Increased risk of death in elderly people with dementia related psychosis. Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for the treatment of people with dementia-related psychosis.

Increased risk of suicidal thoughts and actions. CAPLYTA and antidepressant medicines increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions.

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or the antidepressant medicine is started or when the dose is changed. Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.

Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call a healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying new or worse depression feeling very agitated or restless trouble sleeping acting aggressive, being angry, or violent an extreme increase in activity and talking (mania) suicide attempts new or worse anxiety panic attacks new or worse irritability acting on dangerous impulses other unusual changes in behavior or mood See “

How to take it

Take CAPLYTA exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking CAPLYTA without first talking to your healthcare provider. Take CAPLYTA 1 time each day with or without food. If you take too much CAPLYTA, call your healthcare provider or Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Side effects, and when to stop

” for more information about side effects. What is CAPLYTA? CAPLYTA is a prescription medicine used in adults: to treat schizophrenia alone or along with the medicine lithium or valproate to treat depressive episodes that happen with bipolar I or bipolar II disorder (bipolar depression) along with antidepressant medicines to treat major depressive disorder (MDD) It is not known if CAPLYTA is safe and effective in children.

Who should not take it

Do not take CAPLYTA if you: are allergic to lumateperone or any of the ingredients in CAPLYTA. See the end of this Medication Guide for a complete list of ingredients in CAPLYTA. Before taking CAPLYTA, tell your healthcare provider about all of your medical conditions, including if you: have or have had heart problems or a stroke have or have had low or high blood pressure have or have had diabetes or high blood sugar, or a family history of diabetes or high blood sugar.

have or have had high levels of total cholesterol, LDL cholesterol, or triglycerides or low levels of HDL cholesterol have or have had a low white blood cell count have or have had seizures (convulsions) have or have had kidney or liver problems are pregnant or plan to become pregnant. CAPLYTA may harm your unborn baby.

Taking CAPLYTA during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take CAPLYTA during pregnancy. Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with CAPLYTA.

There is a pregnancy registry for females who are exposed to CAPLYTA during pregnancy. If you become pregnant during treatment with CAPLYTA, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to https://womensmentalhealth.org/research/pregnancyregistry/.

are breastfeeding or plan to breastfeed. CAPLYTA passes into your breast milk. Talk to your healthcare provider about the risks and benefits of breastfeeding and the best way to feed your baby during treatment with CAPLYTA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

CAPLYTA and other medicines may affect each other causing possible serious side effects. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works. Your healthcare provider can tell you if it is safe to take CAPLYTA with your other medicines. Do not start or stop any medicines during treatment with CAPLYTA without first talking to your healthcare provider.

Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.

What to avoid

Do not drive, operate machinery, or do other dangerous activities until you know how CAPLYTA affects you. CAPLYTA may make you drowsy. Do not become too hot or dehydrated during treatment with CAPLYTA. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing.

Drink plenty of water. What are the possible side effects of CAPLYTA? CAPLYTA may cause serious side effects, including: Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death. Neuroleptic malignant syndrome (NMS) is a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever changes in your breathing, heart rate, and blood pressure increased sweating confusion stiff muscles Uncontrolled body movements (tardive dyskinesia).

CAPLYTA may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking CAPLYTA. Tardive dyskinesia may also start after you stop taking CAPLYTA. Problems with your metabolism such as: high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take CAPLYTA.

Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start, or soon after you start CAPLYTA, and then regularly during long term treatment with CAPLYTA. Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with CAPLYTA: feel very thirsty feel very hungry feel sick to your stomach need to urinate more than usual feel weak or tired feel confused, or your breath smells fruity increased fat levels (cholesterol and triglycerides) in your blood.

Your healthcare provider should check the fat levels in your blood before you start, or soon after you start CAPLYTA, and then periodically during treatment with CAPLYTA. weight gain. You and your healthcare provider should check your weight before you start and often during treatment with CAPLYTA. Low white blood cell count.

Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA. Decreased blood pressure (orthostatic hypotension). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position. Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.

Seizures (convulsions). Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. See " What should I avoid while taking CAPLYTA? " Problems controlling your body temperature so that you feel too warm. See “ What should I avoid while taking CAPLYTA? ” Difficulty swallowing that can cause food or liquid to get into your lungs.

The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, dry mouth, feeling tired, and diarrhea. CAPLYTA may cause fertility problems in females and males. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of CAPLYTA. Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088.

Storing it

Store CAPLYTA at room temperature between 68°F to 77°F (20°C to 25°C). Keep CAPLYTA and all medicines out of the reach of children.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Lumateperone; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lumateperone

APA 7th

sofidex. (2026, August 2). Lumateperone. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lumateperone

AMA 11th

Lumateperone. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lumateperone

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.